OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson Sells 7,255 Shares

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson sold 7,255 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $3.67, for a total transaction of $26,625.85. Following the transaction, the chief financial officer now owns 206,211 shares in the company, valued at $756,794.37. The trade was a 3.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

OmniAb Trading Up 5.7 %

OABI opened at $3.88 on Friday. The firm has a 50 day moving average of $3.49 and a two-hundred day moving average of $3.91. The firm has a market capitalization of $547.93 million, a PE ratio of -6.26 and a beta of -0.12. OmniAb, Inc. has a 12-month low of $3.10 and a 12-month high of $6.55.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its position in OmniAb by 105.6% during the 3rd quarter. SG Americas Securities LLC now owns 34,858 shares of the company’s stock worth $147,000 after purchasing an additional 17,901 shares during the period. CWC Advisors LLC. acquired a new stake in OmniAb during the third quarter worth about $54,000. China Universal Asset Management Co. Ltd. grew its holdings in OmniAb by 64.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock worth $96,000 after acquiring an additional 8,909 shares during the period. Palumbo Wealth Management LLC raised its position in OmniAb by 12.5% during the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after acquiring an additional 2,744 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its holdings in OmniAb by 6.4% in the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after acquiring an additional 163,038 shares during the period. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on OABI shares. Benchmark reissued a “buy” rating and set a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.